Data on the in vitro and in vivo anti-tumor effects of itraconazole, paclitaxel, and the two in combination in HT-29 and YM-1 cancer cell line and HT-29 colon cancer xenograft models

Abstract

Colon cancer is one of the fatal cancers in the world that metastatic potential and resistance to chemotherapy drugs are outstanding causes of cancer-induced mortality [1], [2], [3], [4]. We have investigated in vitro and in vivo anti-cancer effect of itraconazole and paclitaxel alone and their anti-cancer synergistic effect through MTT assay in YM-1 and HT-29 cell lines and in HT-29 tumor-bearing nude mice. Histopathological experiment was done for further assessment. Also, we evaluated the inhibitory effect of itraconazole on P-gp using specific in vivo biodistribution through ^99mTc-MIBI uptake. ^99mTc-MIBI, a myocardial perfusion imaging agent, is a useful radiotracer in diagnosis of some tumors and the liver and tumor accumulation of ^99mTc-MIBI is changed by P-gp regulators [5], [6], [7], [8]. The data presented in this article are related to the research paper entitled "Itraconazole synergistically increases therapeutic effect of paclitaxel and 99mTc-MIBI accumulation, as a probe of P-gp activity, in HT-29 tumor-bearing nude mice". We hope our preliminary data to be helpful to design the chemotherapy regimen schedule with Itraconazole and Paclitaxel.

Keywords: 99mTc-MIBI; Itraconazole (ITCZ); P-gp regulator; Paclitaxel (PTX).

Fig. 1

Histopathologic findings of liver tissue A: Itraconazole (20 mg/Kg) group B: Itraconazole (20 mg/Kg) + Paclitaxel (20 mg/Kg) group. Hepatic cells showed increased inflammatory cells in itraconazole + paclitaxel groups but were only lower than those in itraconazole 20 mg / kg. H&E staining, Magnification: 40×, Scale bar: 100µm.